BioSpace News Archive

Mirum Pharmaceuticals, Inc. announced that on July 8, 2022, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 43,000 shares of common stock and 21,500 restricted stock units to seven new employees under Mirum’s 2020 Inducement Plan.

Management will Participate in Fireside Chat on TC BioPharm’s Journey as a Successful CGT Startup on July 13, 2022.

Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today reported preliminary results from the second cohort of the Company’s first-in-human Phase 1a study of WP1122.

Aditxt, Inc. has successfully completed a toxicology study that indicates the safety profile of ADI™-100, the Company’s immunotherapeutic technology drug that addresses rejection of transplanted organs, skin allografting, autoimmune diseases and allergies.

Neptune Wellness Solutions Inc. (“Neptune” or the “Company”) (NASDAQ: NEPT) (TSX: NEPT), a diversified and fully integrated health and wellness company focused on plant-based, sustainable and purpose-driven lifestyle brands, today announced its financial and operating results for the three-month and twelve-month periods ending March 31, 2022.

LASEROPTEK Co., Ltd., a developer and manufacturer of world-class lasers for medical aesthetic and dermatology indications, is pleased to announce it signed a nationwide, multi-year, exclusive distribution agreement with Monarch Lasers.

Forecast to 2027,’ thoroughly examines the Carotid Stents System industry to provide essential data & information for the targeted readers.

The global Amifostine market size is estimated to be worth US$ 50 million in 2021 and is forecast to a readjusted size of US$ 58 million by 2030 with a CAGR of 2.1% during the forecast period 2022-2030.